HilleVax, Inc. (HLVX)
| Market Cap | 101.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -106.50M |
| Shares Out | 49.61M |
| EPS (ttm) | -2.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,417 |
| Open | 2.070 |
| Previous Close | 2.050 |
| Day's Range | 2.030 - 2.090 |
| 52-Week Range | 1.340 - 2.350 |
| Beta | 0.76 |
| Analysts | Hold |
| Price Target | 2.33 (+14.22%) |
| Earnings Date | Aug 7, 2025 |
About HLVX
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for HLVX stock is "Hold." The 12-month stock price target is $2.33, which is an increase of 14.22% from the latest price.
News
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as...
Frazier Life Sciences Appoints Aditya Kohli to Partner
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Aditya Kohli, Ph.D., to Partner. ...
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adult...
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
$245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine can...
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
Stakeholders Of HilleVax Inc Are Urged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
Stakeholders Of Hillevax Inc Are Encouraged By The Schall Law Firm To Join The Alleged Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
Stakeholders Of HilleVax Inc Are Encouraged By The Schall Law Firm To Participate In The Alleged Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
HilleVax, Inc. (HLVX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. (“HilleVax” or “the C...
HLVX Investors Are Invited By The Schall Law Firm To Join Its Investigation Into Alleged Securities Fraud At HilleVax Inc.
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
The Schall Law Firm Invites HLVX Investors To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
HLVX Investors Are Welcomed By The Schall Law Firm To Join Its Inquiry Into Suspected Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Of Alleged Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
The Schall Law Firm Encourages HLVX Stakeholders To Join Its Probe Into Suspected Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
The Schall Law Firm Invites HLVX Stakeholders To Participate In Its Investigation Into Alleged Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
Stakeholders Of HLVX Are Urged To Join The Schall Law Firm's Investigation Of Securities Fraud At HilleVax Inc
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
HLVX Stakeholders Are Encouraged To Participate In The Securities Fraud Investigation Of HilleVax Inc Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("...
HLVX Stakeholders Are Invited To Join The HilleVax Inc Securities Fraud Probe Conducted By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("H...
Gold Falls Over 1%; HilleVax Shares Plunge
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday.
Investors In HLVX Can Participate In The Securities Fraud Investigation Of HilleVax Inc With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("H...
HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--HLVX Investors Have Opportunity to Join HilleVax, Inc. Securities Fraud Investigation with the Schall Law Firm.
Vaccine Developer HilleVax Stock Nosedives On Monday - Here's Why
Shares of vaccine-developer HilleVax Inc HLVX are down on Monday on a session volume of over 7 million as per data from Benzinga Pro.
HilleVax shares plummet after norovirus vaccine fails in mid-stage study
Shares of biotech company HilleVax plunged 88.6% to $1.60 in premarket trade on Monday, after its vaccine to prevent gastroenteritis caused by norovirus failed to meet the main goal of a mid-stage tri...